Author Interviews, Diabetes, Heart Disease / 06.09.2019
Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure
MedicalResearch.com Interview with:
Prof. John McMurray
Professor of Cardiology
Institute of Cardiovascular & Medical Sciences
University of Glasgow
MedicalResearch.com: What is the background for this study?
Response: SGLT2 inhibitors prevent the development of heart failure (HF) in patients with type 2 diabetes (T2D) – can they be used to treat patients with established heart failure? Also, although introduced as a glucose-lowering treatment for T2D, experimental evidence suggests these drugs may have non-glucose mediated benefits. So, might they be a treatment for HF even in patients without diabetes? (more…)